Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9786461 | 1.00 | LMNA (0.42) | LMNAALDH1A1ESR1POLBESR2 | |
| SCHEMBL943558 | 0.83 | LMNA (0.38) | LMNAALDH1A1ESR1POLBESR2 | |
| SCHEMBL6889186 | 0.77 | LMNA (0.48) | LMNATDP1 | |
| SCHEMBL27154341 | 0.77 | LMNA (0.48) | LMNAALDH1A1 | |
| SCHEMBL6889182 | 0.77 | LMNA (0.48) | LMNATDP1 | |
| SCHEMBL4377419 | 0.77 | LMNA (0.48) | LMNATDP1 | |
| Butane SCHEMBL11523420 | 0.76 | LMNA (0.48) | LMNAALDH1A1 | |
| SCHEMBL10633540 | 0.75 | LMNA (0.46) | LMNATDP1 | |
| SCHEMBL10636719 | 0.75 | LMNA (0.46) | LMNAALDH1A1 | |
| SCHEMBL5907461 | 0.74 | LMNA (0.57) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1535914-B1 | PROCESSES FOR PRODUCING EPOXYTRIAZOLE DERIVATIVE AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL CO (JP) | 2011-11-02 | — | — | EP | disclosed |
| EP-1693358-B1 | PROCESS FOR PRODUCING EPOXYTRIAZOLE COMPOUND AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL CO (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-7297802-B2 | Production methods of epoxytriazole derivative and intermediate therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-20 | — | — | US | disclosed |
| EP-1693358-A1 | PROCESS FOR PRODUCING EPOXYTRIAZOLE COMPOUND AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL CO., LTD. (JP) | 2006-08-23 | — | — | EP | disclosed |
| EP-1535914-A1 | PROCESSES FOR PRODUCING EPOXYTRIAZOLE DERIVATIVE AND INTERMEDIATE THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-6884892-B2 | Production methods of epoxytriazole derivative and intermediate therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-04-26 | — | — | US | disclosed |
| US-20040267024-A1 | Production methods of epoxytriazole derivative and intermediate therefor | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-12-30 | — | — | US | disclosed |
| US-20030236419-A1 | Production methods of epoxytriazole derivative and intermediate therefor | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267024-A1 | Production methods of epoxytriazole derivative and intermediate therefor | ERG28, CYP51A1, SOAT2 | LMNA 4345/4885ALDH1A1 967/4885ESR1 2627/4885 |
| US-20030236419-A1 | Production methods of epoxytriazole derivative and intermediate therefor | ERG28, CYP51A1, SOAT2 | LMNA 4345/4885ALDH1A1 967/4885ESR1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.